Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism
NEW YORK, Aug. 16, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled “Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 […]
